{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:39:08Z","timestamp":1787495948460,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["190281"],"award-info":[{"award-number":["190281"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["190275"],"award-info":[{"award-number":["190275"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["223204"],"award-info":[{"award-number":["223204"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007872","name":"Grieg Foundation","doi-asserted-by":"publisher","award":["WI206347"],"award-info":[{"award-number":["WI206347"]}],"id":[{"id":"10.13039\/501100007872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007872","name":"Grieg Foundation","doi-asserted-by":"publisher","award":["9529854"],"award-info":[{"award-number":["9529854"]}],"id":[{"id":"10.13039\/501100007872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007872","name":"Grieg Foundation","doi-asserted-by":"publisher","award":["912252"],"award-info":[{"award-number":["912252"]}],"id":[{"id":"10.13039\/501100007872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["273354"],"award-info":[{"award-number":["273354"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["SKGJ-MED-020"],"award-info":[{"award-number":["SKGJ-MED-020"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010905","name":"Illumina Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2025.104672","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:30:22Z","timestamp":1765413022000},"page":"104672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-0686","authenticated-orcid":false,"given":"Christina","family":"Engebrethsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synn\u00f8ve","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari E.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel A.M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rnar","family":"Gilje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil S.","family":"Blix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Espelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Minsaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reidun","family":"Lillest\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegunn S.","family":"Aase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per E.","family":"L\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans P.","family":"Eikesdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-1655","authenticated-orcid":false,"given":"Stian","family":"Knappskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.breast.2025.104672_bib1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/cncr.22789","article-title":"Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer","volume":"110","author":"Semiglazov","year":"2007","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.breast.2025.104672_bib4","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/annonc\/mds132","article-title":"Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\/2006-03, a multicenter, randomized, phase-II study","volume":"23","author":"Alba","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-014-3183-4","article-title":"NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer","volume":"148","author":"Palmieri","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.breast.2025.104672_bib6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor\u2013positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104672_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(19)30786-7","article-title":"Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104672_bib8","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume":"29","author":"Cottu","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1016\/j.breast.2025.104672_bib10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.breast.2025.104672_bib11","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","article-title":"NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial","volume":"37","author":"Johnston","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","article-title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","volume":"32","author":"Eikesdal","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104672_bib14","first-page":"7","article-title":"Homologous recombination deficiency across subtypes of primary breast cancer","author":"Yndestad","year":"2023","journal-title":"Jco Precision Oncology"},{"issue":"9814","key":"10.1016\/j.breast.2025.104672_bib15","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100\u2008000 women in 123 randomised trials","volume":"379","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.breast.2012.03.011","article-title":"Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials","volume":"21","author":"Shao","year":"2012","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib17","article-title":"Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer","author":"Zaheed","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/bjc.1977.42","article-title":"Assessment of response to therapy in advanced breast cancer","volume":"35","author":"Hayward","year":"1977","journal-title":"British journal of cancer"},{"issue":"7","key":"10.1016\/j.breast.2025.104672_bib20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nm.3886","article-title":"Subclonal diversification of primary breast cancer revealed by multiregion sequencing","volume":"21","author":"Yates","year":"2015","journal-title":"Nature medicine"},{"key":"10.1016\/j.breast.2025.104672_bib21","author":"Fisher","year":"2014","journal-title":"2x2 and 2x3 exact test command line utility: Free Software Foundation"},{"issue":"8","key":"10.1016\/j.breast.2025.104672_bib22","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.104672_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920973130","article-title":"The run-in phase of the prospective WSG-ADAPT HR+\/HER2\u2013 trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer","volume":"12","author":"Nitz","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.951s.11.2","article-title":"Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival","volume":"11","author":"Dowsett","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.breast.2025.104672_bib26","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104672_bib27","doi-asserted-by":"crossref","first-page":"113358","DOI":"10.1016\/j.ejca.2023.113358","article-title":"Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive\/HER2-negative early breast cancer: a systematic review and meta-analysis","volume":"194","author":"Martins-Branco","year":"2023","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.breast.2025.104672_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.breast.2025.104672_bib29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-Positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104672_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"npj Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104672_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.breast.2025.104672_bib32","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104672_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.breast.2025.104672_bib34","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104672_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1078-0432.CCR-21-1628","article-title":"Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+\/HER2\u2212 breast cancer","volume":"28","author":"Dowsett","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.breast.2025.104672_bib36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-Receptor\u2013Positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.breast.2025.104672_bib38","first-page":"38","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104672_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial\u2013mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.breast.2025.104672_bib40","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","article-title":"The cell-cell adhesion molecule E-cadherin","volume":"65","author":"van Roy","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib41","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.breast.2025.104672_bib42","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1111\/jcmm.15140","article-title":"E-cadherin deregulation in breast cancer","volume":"24","author":"Corso","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"25","key":"10.1016\/j.breast.2025.104672_bib43","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2015.60.8133","article-title":"Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial","volume":"33","author":"Metzger Filho","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104672_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2025.104672_bib45","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2025.104672_bib46","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10549-011-1735-4","article-title":"Invasive lobular carcinoma: response to neoadjuvant letrozole therapy","volume":"130","author":"Dixon","year":"2011","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625008914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625008914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:30:05Z","timestamp":1773919805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625008914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"alternative-id":["S0960977625008914"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104672","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104672"}}